Cargando…

Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score–Matched Study

PURPOSE: The purpose of the present study was to compare the long-term effectiveness and safety of newly initiated anticoagulation with edoxaban (EDO) versus uninterrupted vitamin K antagonist (VKA) therapy in patients with atrial fibrillation (AF) scheduled for transesophageal echocardiogram (TEE)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rago, Anna, Papa, Andrea Antonio, Attena, Emilio, Parisi, Valentina, Golino, Paolo, Nigro, Gerardo, Russo, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452548/ https://www.ncbi.nlm.nih.gov/pubmed/32946035 http://dx.doi.org/10.1007/s10557-020-07078-7

Ejemplares similares

Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study
por: Rago, Anna, et al.
Publicado: (2021)

Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
por: Russo, Vincenzo, et al.
Publicado: (2019)

Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation
por: Carbone, Andreina, et al.
Publicado: (2022)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
por: Rago, Anna, et al.
Publicado: (2023)

Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study
por: NIGRO, GERARDO, et al.
Publicado: (2012)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis
por: Fiedler, Lukas, et al.
Publicado: (2021)

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial
por: Lip, Gregory Y. H., et al.
Publicado: (2020)

Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
por: Russo, Vincenzo, et al.
Publicado: (2020)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

Atrial Fibrillation and Beta Thalassemia Major: The Predictive Role of the 12-lead Electrocardiogram Analysis
por: Russo, Vincenzo, et al.
Publicado: (2014)

Single-Chamber Leadless Cardiac Pacemaker in Patients Without Atrial Fibrillation: Findings From Campania Leadless Registry
por: Russo, Vincenzo, et al.
Publicado: (2022)

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
por: Ezekowitz, Michael D, et al.
Publicado: (2018)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Pharmacological cardioversion for atrial fibrillation and flutter
por: Cordina, J, et al.
Publicado: (2006)

Atrial fibrillation cardioversion following acupuncture
por: Dilber, Dario, et al.
Publicado: (2015)

Rivaroxaban in atrial fibrillation cardioversion: an update
por: Lavalle, Carlo, et al.
Publicado: (2019)

How to Optimize Cardioversion of Atrial Fibrillation
por: Airaksinen, K. E. Juhani
Publicado: (2022)

A Cardioversion and Renal Dysfunction Cascade: Cardioversion for Atrial Fibrillation, Acute Kidney Injury, and Recurrence of Atrial Fibrillation
por: Asemota, Iriagbonse R, et al.
Publicado: (2020)

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
por: Goette, Andreas, et al.
Publicado: (2018)

COVID-19 and Heart: From Clinical Features to Pharmacological Implications
por: Russo, Vincenzo, et al.
Publicado: (2020)

Inappropriate shocks due to air entrapment in patients with subcutaneous implantable cardioverter‐defibrillator: A meta‐summary of case reports
por: Iavarone, Michele, et al.
Publicado: (2022)

Atrial fibrillation burden in Myotonic Dystrophy type 1 patients implanted with dual chamber pacemaker: the efficacy of the overdrive atrial algorithm at 2 year follow-up
por: RUSSO, VINCENZO, et al.
Publicado: (2013)

Current Status of Internal Cardioversion in Atrial Fibrillation
por: Plewan, Andreas, et al.
Publicado: (2002)

Ogilvie's Syndrome following Cardioversion for Atrial Fibrillation
por: Al-Halawani, Moh'd, et al.
Publicado: (2014)

Chemical Cardioversion of Atrial Fibrillation with Calcium Gluconate
por: Serhat, A, et al.
Publicado: (2012)

Timing of cardioversion in atrial fibrillation: the sooner the better?
por: Capranzano, Piera, et al.
Publicado: (2020)

Defining the benefit: Cardioversion of persistent atrial fibrillation
por: Nedios, Sotirios, et al.
Publicado: (2021)

A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2022)

Prediction of Successful Pharmacological Cardioversion in Acute Symptomatic Atrial Fibrillation: The Successful Intravenous Cardioversion for Atrial Fibrillation (SIC-AF) Score
por: Niederdöckl, Jan Daniel, et al.
Publicado: (2022)

Clinical Outcome of Hospitalized COVID-19 Patients with History of Atrial Fibrillation
por: Russo, Vincenzo, et al.
Publicado: (2022)

Epicardial Adipose Tissue and Cardiac Arrhythmias: Focus on Atrial Fibrillation
por: Conte, Maddalena, et al.
Publicado: (2022)

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
por: Lin, Shin-Yi, et al.
Publicado: (2021)

The Role of Biphasic Shocks for Transthoracic Cardioversion of Atrial Fibrillation
por: Walsh, Simon J, et al.
Publicado: (2005)

Planning and monitoring of patients for electrical cardioversion for atrial fibrillation
por: Deuling, J. H. H., et al.
Publicado: (2011)

Comparison of monophasic versus biphasic cardioversion for atrial fibrillation
por: Vaisman, M, et al.
Publicado: (2005)

Rare Coronary Embolism Secondary to Cardioversion of Atrial Fibrillation
por: Alkhatib, Deya, et al.
Publicado: (2022)

QTc Dynamics Following Cardioversion for Persistent Atrial Fibrillation
por: Younis, Arwa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_15kngdttt129os5mskur0oba78